Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28698242 | 0.85 | RAF1 (0.56) | RAF1BRAF | |
| SCHEMBL16094566 | 0.84 | BRAF (0.71) | RAF1BRAF | |
| SCHEMBL16093973 | 0.83 | RAF1 (0.57) | RAF1BRAF | |
| SCHEMBL22487979 | 0.80 | RAF1 (0.56) | RAF1BRAF | |
| SCHEMBL22488217 | 0.79 | RAF1 (0.44) | RAF1BRAF | |
| SCHEMBL22468361 | 0.79 | RAF1 (0.43) | RAF1BRAF | |
| SCHEMBL30379136 | 0.78 | RAF1 (0.50) | RAF1BRAF | |
| SCHEMBL26087687 | 0.78 | RAF1 (0.50) | RAF1BRAF | |
| SCHEMBL30378784 | 0.77 | RAF1 (0.49) | RAF1BRAF | |
| SCHEMBL26088944 | 0.77 | RAF1 (0.49) | RAF1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230081390-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2023-03-16 | — | — | US | disclosed |
| EP-3941922-A1 | INHIBITORS OF RAF KINASES | Kinnate Biopharma Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020198058-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020198058-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2020-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230081390-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, ARAF | RAF1 2/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.